Praxis Precision Medicines (PRAX) Enters Into Licensing and Research Collaboration With Remagine Labs

Praxis Precision Medicines (PRAX) Enters Into Licensing and Research Collaboration With Remagine Labs Muhammad Ali Khalid Wed, July 15, 2026 at 4:01 PM GMT+2 2 min read PRAX Praxis Precision Medicines Inc. (NASDAQ: PRAX ) is one of the 10 affordable biotech stocks to buy right now . On July 7, Praxis Precision Medicines Inc.

(NASDAQ:PRAX) and Remagine Labs disclosed a research partnership and license agreement to design an iontophoretic transdermal patch for the delivery of ulixacaltamide. Ulixacaltamide is a strongly targeted T-type calcium channel inhibitor of Praxis in the essential tremor development. create jobs 51/Shutterstock.

com Both companies will use Remagine's platform, developed for precise, multi-day sustained skin-based dosing, for ulixacaltamide, supporting Praxis's oral program. On June 29, Praxis Precision Medicines disclosed that the FDA allowed a three-month extension to the NDA review for relutrigine, a treatment for epileptic and SCN2A & SCN8A developmental encephalopathy. The new PDUFA target date has been extended from September 27 to December 27.

The extension came after the company had submitted further sensitivity analyses around the current clinical results, which were labeled as a "major amendment" by the FDA. No new clinical trials were requested, and the company was not asked to address any safety or manufacturing issues. Praxis is optimistic about the data on relutrigine and has prepared for the eventual launch of the product.

Praxis Precision Medicines Inc. (NASDAQ:PRAX) is involved in developing therapies to cure disorders related to the central nervous system, which are characterized by neuronal excitation-inhibition imbalance. These disorders include epilepsy, movement disorders, and depression.

The company utilizes its proprietary platforms like Cerebrum and Solidus to target such imbalances. While we acknowledge the potential of PRAX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the   best short-term AI stock .

READ NEXT:  33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years . Disclosure: None. Follow Insider Monkey on Google News .